Developer docs
API playgroundTry for free, no card

Search company profiles

Hongene Biotechnology

Full company profile

uuid0009olk

Namestring
Hongene Biotechnology
Legal namestring
Hongene Biotech Corporation
Websiteurl
hongene.com
Company typeenum
Private
Founded yearint
1998
Descriptiontext

Hongene Biotech Corporation is a privately-held, vertically-integrated contract development and manufacturing organization (CDMO) specializing in nucleic acid manufacturing, founded in 1998 and headquartered with operations in Shanghai (China), Union City (USA), Hamburg (Germany), and Tokyo (Japan). The company converts nearly three decades of RNA-focused expertise into a single-source platform that spans raw materials — phosphoramidites, GalNAc conjugates, linkers, nucleoside triphosphates, cap analogs, enzymes, and other reagents across more than 2,000 SKUs — through to GMP-grade oligonucleotide and mRNA drug product. Service offerings are organized around three CDMO lines (oligonucleotide, mRNA, and custom synthesis), and the company also distributes standardized reagents direct-to-customer through an e-commerce storefront (shop.hongene.com).

The underlying technology platform combines oligonucleotide synthesis, mRNA synthesis, and lipid nanoparticle (LNP) delivery capabilities, augmented by an inbound license for exNA oligonucleotide technology from UMass Chan Medical School. Hongene addresses pharmaceutical and biotechnology customers developing antisense oligonucleotides, siRNA, mRNA vaccines, gene editing components, and diagnostic reagents, with additional reach into global health initiatives via a Bill & Melinda Gates Foundation grant to develop patent-free cap analogs for mRNA vaccines targeting low- and middle-income countries.

Hongene operates a B2B revenue model combining enterprise CDMO project engagements with a hardware-like raw materials and reagents catalog. Customers are reached through direct field sales for CDMO contracts (accompanied by regulatory support) and self-service online ordering for catalog products. Pricing is quote-based and not publicly disclosed. Strategic posture is supported by a stacked partnership cadence across ReciBioPharm (gene editing CDMO), UMass Chan (exNA licensing), the Gates Foundation (cap analogs for global health), and SiranBio (CDMO support for chronic hepatitis B siRNA), positioning the company within the USD 17.42 billion (2025) nucleic acid therapeutics CDMO market and the USD 2.22 billion (2025) mRNA synthesis raw materials market, both projected to grow at roughly 14% CAGR through the next decade.

Short descriptiontext

Hongene Biotech Corporation is a vertically-integrated CDMO manufacturing nucleic acid raw materials (2,000+ SKUs) and providing oligonucleotide, mRNA, and custom synthesis CDMO services to pharmaceutical and biotech companies developing RNA-based therapeutics globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersUnion City, United States
HQ citystring
Union City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nucleic acid manufacturing, oligonucleotide CDMO, mRNA synthesis reagents, phosphoramidite raw materials, GMP drug product manufacturing
Industry4 codes
PRIMARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Medicinal Chemicals & Botanical Products2833
Product category
Nucleic Acid CDMO & Raw Materials Manufacturing
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1CDMO Services
TypeProfessional Services
Description

Contract Development and Manufacturing Organization (CDMO) services providing integrated oligonucleotide and mRNA manufacturing from raw materials to GMP drug product for biotech and pharma clients

hongene.com
2Technology Licensing
TypeOne Time License
Description

Licensing of proprietary technologies including exNA oligonucleotide technology to other manufacturers and research institutions

marketsandmarkets.com
3Raw Materials and Reagents Sales
TypeHardware Sales
Description

Sale of raw materials including phosphoramidites, nucleotides, cap analogs, enzymes, and other reagents for oligonucleotide and mRNA synthesis, supporting both research and commercial scale manufacturing

hongene.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Hongene Biotech Corporation manufactures nucleic acid raw materials (phosphoramidites, cap analogs, nucleotides, enzymes, GalNAc conjugates, linkers) and provides contract development and manufacturing organization (CDMO) services for oligonucleotide and mRNA therapeutics. The platform is vertically integrated from raw materials to GMP drug product, serving pharmaceutical and biotechnology customers with a portfolio of more than 2,000 SKUs. End-to-end engagement covers antisense oligonucleotides, siRNA, mRNA vaccines, and gene editing therapies, with global manufacturing presence in the USA, Germany, Japan, and China.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Global nucleic acid therapeutics CDMO market growing at 14.18% CAGR from USD 17.42 billion (2025) to USD 57.37 billion (2034)
+1 more record
Product overview1 text field

Hongene Biotech Corporation operates as a vertically-integrated CDMO (Contract Development and Manufacturing Organization) specializing in nucleic acid manufacturing with a portfolio of over 2,000 SKUs. The company offers a comprehensive product portfolio spanning raw materials for oligonucleotide and mRNA synthesis (including Phosphoramidites, PMO, PNA, GalNAc Conjugates, Cap Analogs, Nucleotides, and Enzymes), diagnostic reagents, and finished mRNA products. These raw materials feed into three main service offerings: Oligonucleotide CDMO Services, mRNA CDMO Services, and Custom Synthesis Services, enabling end-to-end support from raw material supply through GMP drug product manufacturing for RNA-based therapeutics and vaccines.

Product and service28 records
1Phosphoramidites
CategoryRaw Material - Oligonucleotide Synthesis
Description

Phosphoramidite building blocks used in oligonucleotide synthesis, forming the phosphodiester backbone of DNA and RNA sequences for research and therapeutic applications.

2PMO (Phosphorodiamidate Morpholino Oligomers)
CategoryRaw Material - Oligonucleotide Synthesis
Description

Synthetic oligonucleotide analogs with a morpholino ring structure, used in antisense therapy applications requiring enhanced stability and binding affinity.

3PNA (Peptide Nucleic Acids)
CategoryRaw Material - Oligonucleotide Synthesis
Description

Synthetic DNA analogs with a peptide backbone, offering high thermal stability and resistance to nucleases and proteases for diagnostic and therapeutic applications.

4Succinates
CategoryRaw Material - Oligonucleotide Synthesis
Description

Succinylated nucleoside derivatives used as protecting groups in oligonucleotide synthesis workflows.

5Dyes & Quenchers
CategoryRaw Material - Oligonucleotide Synthesis
Description

Fluorescent dyes and quenchers for oligonucleotide labeling used in diagnostics, qPCR, and fluorescence-based detection assays.

6GalNAc Conjugates
CategoryRaw Material - Oligonucleotide Synthesis
Description

N-acetylgalactosamine conjugates enabling targeted delivery of oligonucleotides to hepatocytes via asialoglycoprotein receptor-mediated uptake for liver-targeted therapeutics.

7Solid Support
CategoryRaw Material - Oligonucleotide Synthesis
Description

Solid-phase synthesis supports used as the foundation for oligonucleotide synthesis on automated synthesizers.

8Oligo Reagents
CategoryRaw Material - Oligonucleotide Synthesis
Description

Auxiliary reagents and chemicals required for oligonucleotide synthesis processes.

9Enzymes & Related Buffer for mRNA
CategoryRaw Material - mRNA Synthesis
Description

Enzymes and optimized buffers for mRNA synthesis, including capping enzymes and processing components for in vitro transcription workflows.

10Nucleotides for mRNA
CategoryRaw Material - mRNA Synthesis
Description

Nucleotide triphosphates and modified nucleotides used as building blocks in mRNA synthesis, including modified bases for enhanced stability and reduced immunogenicity.

11Stock mRNA
CategoryFinished Product - mRNA
Description

Pre-synthesized mRNA products available for research and development use.

12Cap Analogs
CategoryRaw Material - mRNA Synthesis
Description

mRNA capping analogs, including natural and modified cap structures, for enhancing translation efficiency and stability of mRNA therapeutics.

13Kits for mRNA
CategoryKits - mRNA Synthesis
Description

Complete kit solutions for mRNA synthesis, containing all necessary components for in vitro transcription and processing.

14LNP Devices
CategoryDevice - mRNA Delivery
Description

Lipid nanoparticle formulation devices for mRNA delivery system development.

15Nucleotides for Diagnostics
CategoryRaw Material - Diagnostics
Description

Nucleotide reagents specifically formulated for diagnostic applications including qPCR and next-generation sequencing.

16Phosphoramidites for Diagnostics
CategoryRaw Material - Diagnostics
Description

Diagnostic-grade phosphoramidite building blocks meeting purity requirements for clinical and research diagnostic assays.

17Dyes & Quenchers for Diagnostics
CategoryRaw Material - Diagnostics
Description

Diagnostic-specific fluorescent dyes and quenchers for molecular diagnostics and point-of-care testing applications.

18Kits for Diagnostics
CategoryKits - Diagnostics
Description

Diagnostic kit solutions for nucleic acid testing and molecular diagnostics.

19Nucleosides
CategoryRaw Material - Other
Description

Natural and modified nucleosides serving as fundamental building blocks for oligonucleotide and nucleoside analog synthesis.

20Protected Nucleosides (PNS)
CategoryRaw Material - Other
Description

Protection-group-modified nucleosides required for selective activation and controlled synthesis in oligonucleotide manufacturing.

21Nucleotides
CategoryRaw Material - Other
Description

Natural and modified nucleotides, including nucleoside mono-, di-, and triphosphates, for various nucleic acid applications.

22Dyes & Quenchers Precursor
CategoryRaw Material - Other
Description

Precursor compounds for fluorescent dye and quencher synthesis, used in labeled oligonucleotide production.

23Linkers
CategoryRaw Material - Other
Description

Bifunctional linker molecules for conjugating oligonucleotides to targeting moieties, labels, or surfaces.

24Sugars
CategoryRaw Material - Other
Description

Sugar derivatives including ribose and deoxyribose analogs used in nucleoside and nucleotide analog synthesis.

25Reagents
CategoryRaw Material - Other
Description

General chemical reagents used in nucleic acid synthesis and processing workflows.

26Oligonucleotide CDMO Services
CategoryCDMO Service - Oligonucleotide
Description

Contract development and manufacturing organization services for oligonucleotide therapeutics, providing integrated support from raw materials through GMP drug product.

27mRNA CDMO Services
CategoryCDMO Service - mRNA
Description

End-to-end mRNA therapeutic development and manufacturing services including synthesis, capping, purification, and formulation.

28Custom Synthesis Services
CategoryCDMO Service - Custom Synthesis
Description

Bespoke synthesis services for custom oligonucleotides, modified nucleic acids, and specialized nucleoside analogs meeting specific research or manufacturing requirements.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1SiranBio
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-19
Description

CDMO support for SiranBio's SA1211 program, a dual-target siRNA candidate for chronic hepatitis B. Hongene provided integrated services across multiple stages from raw materials to regulatory support, demonstrating capabilities for complex oligonucleotide therapeutics.

chemanager-online.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-09-01
Description

Licensing deal for exNA oligonucleotide technology, with Hongene supplying the technology to the market under the licensing agreement. This extends Hongene's advanced oligonucleotide capabilities through inbound IP licensing.

3ReciBioPharm
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-19
Description

Partnership to provide end-to-end gene editing CDMO services, integrating sgRNA production at ReciBioPharm's facility. The collaboration aims to streamline the development and manufacturing process for gene editing therapies by reducing supply chain complexity for developers.

recipharm.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

GenScript offers gene synthesis, oligonucleotide manufacturing, and CDMO services including mRNA and gene therapy — overlapping with Hongene's raw materials, custom synthesis, and nucleic acid CDMO capabilities.

2Nitto Denko Avecia
TypeDirect peer
Description

Avecia is a dedicated oligonucleotide CDMO offering development and GMP manufacturing for antisense and siRNA therapeutics — directly comparable to Hongene's oligonucleotide CDMO service line.

TypeDirect peer
Description

TriLink is a specialist in mRNA raw materials (cap analogs, NTPs, CleanCap) and CDMO services, making it one of the closest direct peers to Hongene's mRNA raw materials and mRNA CDMO business.

TypeDirect peer
Description

LGC Biosearch Technologies manufactures oligonucleotides, probes, and qPCR/diagnostic reagents — overlapping with Hongene's raw materials catalog and diagnostic reagent product lines.

TypeBroad incumbent
Description

Thermo Fisher operates a massive life sciences services and CDMO business (Patheon) that includes nucleic acid and oligonucleotide offerings as part of a broad portfolio — a broad incumbent against which Hongene's focused nucleic acid platform competes.

TypeDirect peer
Description

Aldevron, now part of Danaher, is a leading nucleic acid CDMO providing plasmid DNA, mRNA, and recombinant protein services — directly comparable to Hongene's CDMO offerings in mRNA and gene editing support.

TypeDirect peer
Description

Eurofins Genomics provides custom oligonucleotide synthesis and nucleic acid services at scale across multiple continents, comparable to Hongene's catalog and custom synthesis offerings for research and commercial customers.

TypeDirect peer
Description

Wuxi STA is the largest China-based oligonucleotide and small-molecule CDMO and the most direct competitor to Hongene in nucleic acid contract manufacturing, offering overlapping oligonucleotide and mRNA CDMO services to global biotech.

9Asymchem Laboratories
TypeDirect peer
Description

Asymchem is a China-headquartered CDMO expanding into oligonucleotide and nucleic acid manufacturing; it competes with Hongene particularly in serving Asian and global biotech CDMO needs.

TypeDirect peer
Description

BioSpring is a Germany-based oligonucleotide CDMO with vertically integrated capabilities across raw materials through API, directly competing with Hongene for European oligonucleotide manufacturing customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hongene Biotechnology

Nucleic Acid CDMO & Raw Materials Manufacturinghongene.com

Hongene Biotech Corporation is a vertically-integrated CDMO manufacturing nucleic acid raw materials (2,000+ SKUs) and providing oligonucleotide, mRNA, and custom synthesis CDMO services to pharmaceutical and biotech companies developing RNA-based therapeutics globally.

What Hongene Biotechnology does

Hongene Biotech Corporation is a privately-held, vertically-integrated contract development and manufacturing organization (CDMO) specializing in nucleic acid manufacturing, founded in 1998 and headquartered with operations in Shanghai (China), Union City (USA), Hamburg (Germany), and Tokyo (Japan). The company converts nearly three decades of RNA-focused expertise into a single-source platform that spans raw materials — phosphoramidites, GalNAc conjugates, linkers, nucleoside triphosphates, cap analogs, enzymes, and other reagents across more than 2,000 SKUs — through to GMP-grade oligonucleotide and mRNA drug product. Service offerings are organized around three CDMO lines (oligonucleotide, mRNA, and custom synthesis), and the company also distributes standardized reagents direct-to-customer through an e-commerce storefront (shop.hongene.com).

The underlying technology platform combines oligonucleotide synthesis, mRNA synthesis, and lipid nanoparticle (LNP) delivery capabilities, augmented by an inbound license for exNA oligonucleotide technology from UMass Chan Medical School. Hongene addresses pharmaceutical and biotechnology customers developing antisense oligonucleotides, siRNA, mRNA vaccines, gene editing components, and diagnostic reagents, with additional reach into global health initiatives via a Bill & Melinda Gates Foundation grant to develop patent-free cap analogs for mRNA vaccines targeting low- and middle-income countries.

Hongene operates a B2B revenue model combining enterprise CDMO project engagements with a hardware-like raw materials and reagents catalog. Customers are reached through direct field sales for CDMO contracts (accompanied by regulatory support) and self-service online ordering for catalog products. Pricing is quote-based and not publicly disclosed. Strategic posture is supported by a stacked partnership cadence across ReciBioPharm (gene editing CDMO), UMass Chan (exNA licensing), the Gates Foundation (cap analogs for global health), and SiranBio (CDMO support for chronic hepatitis B siRNA), positioning the company within the USD 17.42 billion (2025) nucleic acid therapeutics CDMO market and the USD 2.22 billion (2025) mRNA synthesis raw materials market, both projected to grow at roughly 14% CAGR through the next decade.

Hongene Biotechnology firmographics

Firmographics
Name
Hongene Biotechnology
Legal name
Hongene Biotech Corporation
Website
https://hongene.com
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
51–100 employees
Short description
Hongene Biotech Corporation is a vertically-integrated CDMO manufacturing nucleic acid raw materials (2,000+ SKUs) and providing oligonucleotide, mRNA, and custom synthesis CDMO services to pharmaceutical and biotech companies developing RNA-based therapeutics globally.
Ownership category
akta.pro rank

Hongene Biotechnology industry classification

Industry
Product category
Nucleic Acid CDMO & Raw Materials Manufacturing
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Nucleic acid manufacturing
  • Oligonucleotide CDMO
  • MRNA synthesis reagents
  • Phosphoramidite raw materials
  • GMP drug product manufacturing

Where Hongene Biotechnology is headquartered

Location

Headquarters

HQ city
Union City
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Hongene Biotechnology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. CDMO Services: Contract Development and Manufacturing Organization (CDMO) services providing integrated oligonucleotide and mRNA manufacturing from raw materials to GMP drug product for biotech and pharma clients
  2. Technology Licensing: Licensing of proprietary technologies including exNA oligonucleotide technology to other manufacturers and research institutions
  3. Raw Materials and Reagents Sales: Sale of raw materials including phosphoramidites, nucleotides, cap analogs, enzymes, and other reagents for oligonucleotide and mRNA synthesis, supporting both research and commercial scale manufacturing

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Hongene Biotechnology product offering

Product offering

Core offering

Hongene Biotech Corporation manufactures nucleic acid raw materials (phosphoramidites, cap analogs, nucleotides, enzymes, GalNAc conjugates, linkers) and provides contract development and manufacturing organization (CDMO) services for oligonucleotide and mRNA therapeutics. The platform is vertically integrated from raw materials to GMP drug product, serving pharmaceutical and biotechnology customers with a portfolio of more than 2,000 SKUs. End-to-end engagement covers antisense oligonucleotides, siRNA, mRNA vaccines, and gene editing therapies, with global manufacturing presence in the USA, Germany, Japan, and China.

Product overview

Hongene Biotech Corporation operates as a vertically-integrated CDMO (Contract Development and Manufacturing Organization) specializing in nucleic acid manufacturing with a portfolio of over 2,000 SKUs. The company offers a comprehensive product portfolio spanning raw materials for oligonucleotide and mRNA synthesis (including Phosphoramidites, PMO, PNA, GalNAc Conjugates, Cap Analogs, Nucleotides, and Enzymes), diagnostic reagents, and finished mRNA products. These raw materials feed into three main service offerings: Oligonucleotide CDMO Services, mRNA CDMO Services, and Custom Synthesis Services, enabling end-to-end support from raw material supply through GMP drug product manufacturing for RNA-based therapeutics and vaccines.

Differentiator

Problem solved

Functional benefit

Products and services

  • Phosphoramidites Phosphoramidite building blocks used in oligonucleotide synthesis, forming the phosphodiester backbone of DNA and RNA sequences for research and therapeutic applications.
  • PMO (Phosphorodiamidate Morpholino Oligomers) Synthetic oligonucleotide analogs with a morpholino ring structure, used in antisense therapy applications requiring enhanced stability and binding affinity.
  • PNA (Peptide Nucleic Acids) Synthetic DNA analogs with a peptide backbone, offering high thermal stability and resistance to nucleases and proteases for diagnostic and therapeutic applications.
  • Succinates Succinylated nucleoside derivatives used as protecting groups in oligonucleotide synthesis workflows.
  • Dyes & Quenchers Fluorescent dyes and quenchers for oligonucleotide labeling used in diagnostics, qPCR, and fluorescence-based detection assays.
  • GalNAc Conjugates N-acetylgalactosamine conjugates enabling targeted delivery of oligonucleotides to hepatocytes via asialoglycoprotein receptor-mediated uptake for liver-targeted therapeutics.
  • Solid Support Solid-phase synthesis supports used as the foundation for oligonucleotide synthesis on automated synthesizers.
  • Oligo Reagents Auxiliary reagents and chemicals required for oligonucleotide synthesis processes.
  • Enzymes & Related Buffer for mRNA Enzymes and optimized buffers for mRNA synthesis, including capping enzymes and processing components for in vitro transcription workflows.
  • Nucleotides for mRNA Nucleotide triphosphates and modified nucleotides used as building blocks in mRNA synthesis, including modified bases for enhanced stability and reduced immunogenicity.
  • Stock mRNA Pre-synthesized mRNA products available for research and development use.
  • Cap Analogs mRNA capping analogs, including natural and modified cap structures, for enhancing translation efficiency and stability of mRNA therapeutics.
  • Kits for mRNA Complete kit solutions for mRNA synthesis, containing all necessary components for in vitro transcription and processing.
  • LNP Devices Lipid nanoparticle formulation devices for mRNA delivery system development.
  • Nucleotides for Diagnostics Nucleotide reagents specifically formulated for diagnostic applications including qPCR and next-generation sequencing.
  • Phosphoramidites for Diagnostics Diagnostic-grade phosphoramidite building blocks meeting purity requirements for clinical and research diagnostic assays.
  • Dyes & Quenchers for Diagnostics Diagnostic-specific fluorescent dyes and quenchers for molecular diagnostics and point-of-care testing applications.
  • Kits for Diagnostics Diagnostic kit solutions for nucleic acid testing and molecular diagnostics.
  • Nucleosides Natural and modified nucleosides serving as fundamental building blocks for oligonucleotide and nucleoside analog synthesis.
  • Protected Nucleosides (PNS) Protection-group-modified nucleosides required for selective activation and controlled synthesis in oligonucleotide manufacturing.
  • Nucleotides Natural and modified nucleotides, including nucleoside mono-, di-, and triphosphates, for various nucleic acid applications.
  • Dyes & Quenchers Precursor Precursor compounds for fluorescent dye and quencher synthesis, used in labeled oligonucleotide production.
  • Linkers Bifunctional linker molecules for conjugating oligonucleotides to targeting moieties, labels, or surfaces.
  • Sugars Sugar derivatives including ribose and deoxyribose analogs used in nucleoside and nucleotide analog synthesis.
  • Reagents General chemical reagents used in nucleic acid synthesis and processing workflows.
  • Oligonucleotide CDMO Services Contract development and manufacturing organization services for oligonucleotide therapeutics, providing integrated support from raw materials through GMP drug product.
  • mRNA CDMO Services End-to-end mRNA therapeutic development and manufacturing services including synthesis, capping, purification, and formulation.
  • Custom Synthesis Services Bespoke synthesis services for custom oligonucleotides, modified nucleic acids, and specialized nucleoside analogs meeting specific research or manufacturing requirements.

Quantifiable outcome

  • Global nucleic acid therapeutics CDMO market growing at 14.18% CAGR from USD 17.42 billion (2025) to USD 57.37 billion (2034)
  • +1 more outcomes

Companies that use Hongene Biotechnology

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Hongene Biotechnology technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Hongene Biotechnology partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • SiranBiocoreStrategic or Co-development Partner · 19 May 2026CDMO support for SiranBio's SA1211 program, a dual-target siRNA candidate for chronic hepatitis B. Hongene provided integrated services across multiple stages from raw materials to regulatory support, demonstrating capabilities for complex oligonucleotide therapeutics.
  • UMass Chan Medical SchoolcoreOEM/ Whitelabel/ Licensing Partner · 1 September 2025Licensing deal for exNA oligonucleotide technology, with Hongene supplying the technology to the market under the licensing agreement. This extends Hongene's advanced oligonucleotide capabilities through inbound IP licensing.
  • ReciBioPharmcoreStrategic or Co-development Partner · 19 November 2024Partnership to provide end-to-end gene editing CDMO services, integrating sgRNA production at ReciBioPharm's facility. The collaboration aims to streamline the development and manufacturing process for gene editing therapies by reducing supply chain complexity for developers.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Hongene Biotechnology competitors and assessment

Company assessment

Direct peers

  • GenScript: GenScript offers gene synthesis, oligonucleotide manufacturing, and CDMO services including mRNA and gene therapy — overlapping with Hongene's raw materials, custom synthesis, and nucleic acid CDMO capabilities.
  • Nitto Denko Avecia: Avecia is a dedicated oligonucleotide CDMO offering development and GMP manufacturing for antisense and siRNA therapeutics — directly comparable to Hongene's oligonucleotide CDMO service line.
  • TriLink BioTechnologies (Maravai LifeSciences): TriLink is a specialist in mRNA raw materials (cap analogs, NTPs, CleanCap) and CDMO services, making it one of the closest direct peers to Hongene's mRNA raw materials and mRNA CDMO business.
  • LGC Biosearch Technologies: LGC Biosearch Technologies manufactures oligonucleotides, probes, and qPCR/diagnostic reagents — overlapping with Hongene's raw materials catalog and diagnostic reagent product lines.
  • Aldevron (Danaher): Aldevron, now part of Danaher, is a leading nucleic acid CDMO providing plasmid DNA, mRNA, and recombinant protein services — directly comparable to Hongene's CDMO offerings in mRNA and gene editing support.
  • Eurofins Genomics: Eurofins Genomics provides custom oligonucleotide synthesis and nucleic acid services at scale across multiple continents, comparable to Hongene's catalog and custom synthesis offerings for research and commercial customers.
  • Wuxi AppTec (STA Pharmaceutical): Wuxi STA is the largest China-based oligonucleotide and small-molecule CDMO and the most direct competitor to Hongene in nucleic acid contract manufacturing, offering overlapping oligonucleotide and mRNA CDMO services to global biotech.
  • Asymchem Laboratories: Asymchem is a China-headquartered CDMO expanding into oligonucleotide and nucleic acid manufacturing; it competes with Hongene particularly in serving Asian and global biotech CDMO needs.
  • BioSpring: BioSpring is a Germany-based oligonucleotide CDMO with vertically integrated capabilities across raw materials through API, directly competing with Hongene for European oligonucleotide manufacturing customers.

Broad incumbents

  • Thermo Fisher Scientific: Thermo Fisher operates a massive life sciences services and CDMO business (Patheon) that includes nucleic acid and oligonucleotide offerings as part of a broad portfolio — a broad incumbent against which Hongene's focused nucleic acid platform competes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Hongene Biotechnology social profiles

Digital presence

Hongene Biotechnology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hongene Biotechnology leadership team

Management profile

Number of profiles

Hongene Biotechnology funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hongene Biotechnology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hongene Biotechnology

What does Hongene Biotechnology do?

Hongene Biotech Corporation manufactures nucleic acid raw materials (phosphoramidites, cap analogs, nucleotides, enzymes, GalNAc conjugates, linkers) and provides contract development and manufacturing organization (CDMO) services for oligonucleotide and mRNA therapeutics. The platform is vertically integrated from raw materials to GMP drug product, serving pharmaceutical and biotechnology customers with a portfolio of more than 2,000 SKUs. End-to-end engagement covers antisense oligonucleotides, siRNA, mRNA vaccines, and gene editing therapies, with global manufacturing presence in the USA, Germany, Japan, and China.

Is Hongene Biotechnology a public or private company?

Hongene Biotechnology is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Hongene Biotechnology founded?

Hongene Biotechnology was founded in 1998. It employs 51 to 100 people.

Where is Hongene Biotechnology based?

Hongene Biotechnology is headquartered in Union City, United States, in the North America region.

How does Hongene Biotechnology make money?

Three revenue lines are on record. CDMO Services are the primary driver. The others are technology Licensing and raw Materials and Reagents Sales.

Who are Hongene Biotechnology's main competitors?

Direct peers on record are GenScript, Nitto Denko Avecia, TriLink BioTechnologies (Maravai LifeSciences), LGC Biosearch Technologies, Aldevron (Danaher), Eurofins Genomics, Wuxi AppTec (STA Pharmaceutical), Asymchem Laboratories and BioSpring. Thermo Fisher Scientific is listed as a broad incumbent.

Does Hongene Biotechnology have an API?

No public API is recorded for Hongene Biotechnology.

What industry is Hongene Biotechnology in?

Hongene Biotechnology's product category is Nucleic Acid CDMO & Raw Materials Manufacturing. Its primary akta.pro industry code is HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA), with a secondary code of HLAGABAF, mRNA/LNP & Nucleic Acid Therapeutics CDMO. Its NAICS code is 325414 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comNewsletter June 2026Aptahem's CEO reported that partner Hongene Biotech produced a test batch of Apta-1 with 99% purity using a new conjugation method. The high purity improves manufacturing efficiency and supports scaling up production. The company plans to explore collaborations with academic partners and research companies.HongeneHongene Biotech Announces Grant to Expand Global Access to mRNA Vaccine Raw MaterialsHongene Biotech announced receipt of a grant from the Gates Foundation to develop high-quality, affordable, and patent-free cap analogs for mRNA vaccine production, with a focus on strengthening global vaccine supply chains for low- and middle-income countries. The project includes provisions for open dissemination of results and technologies to ensure broad accessibility and support vaccine equity. This initiative positions Hongene to deliver end-to-end solutions for RNA-based medicines while advancing global health readiness.PharmiWeb.comHongene Biotech Announces Grant to Expand Global Access to mRNA Vaccine Raw MaterialsHongene Biotech announced receipt of a grant from the Gates Foundation to develop high-quality, affordable, and patent-free cap analogs for mRNA vaccine production. The initiative aims to strengthen global vaccine supply chains and ensure equitable access for low- and middle-income countries by scaling production of critical capping reagents. Technologies and knowledge from the project will be made available broadly at affordable pricing, with licensing provisions enabling public sector and nonprofit manufacturers to expand vaccine access.news.cision.comNewsletter December 2025Swedish biotech company Aptahem has released its CEO's year-end newsletter for 2025, highlighting clinical progress on its Apta-1 drug candidate for sepsis treatment, strengthened intellectual property with new patent filings and approvals in China and South Korea, and deepened manufacturing collaboration with Hongene Biotech. The company also announced plans to potentially establish a presence on U.S. capital markets and participate in the J.P. Morgan Healthcare Conference in January 2026, while completing two financings totaling over SEK 10 million. CEO Mikael Lindstam expressed optimism about entering 2026 with strengthened positioning and Phase 2 study preparations underway.RecipharmRevolutionising gene editing with end-to-end CDMO servicesReciBioPharm announced a partnership with Hongene Biotech to provide end-to-end contract development and manufacturing organization (CDMO) services for gene editing therapies. This collaboration integrates Hongene’s sgRNA synthesis technology into ReciBioPharm’s Watertown facility, allowing developers to streamline the production process from sgRNA synthesis to fill-finish under one roof.